Growth Metrics

Arrowhead Pharmaceuticals (ARWR) Debt to Equity (2016 - 2025)

Arrowhead Pharmaceuticals' Debt to Equity history spans 11 years, with the latest figure at $0.36 for Q4 2025.

  • For Q4 2025, Debt to Equity fell 95.11% year-over-year to $0.36; the TTM value through Dec 2025 reached $0.36, down 95.11%, while the annual FY2025 figure was $0.51, 75.4% down from the prior year.
  • Debt to Equity reached $0.36 in Q4 2025 per ARWR's latest filing, down from $0.51 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $7.3 in Q4 2024 to a low of $0.36 in Q4 2025.